No benefit with simvastatin add-on therapy in MS


The most recent results from the SIMCOMBIN trial of combined beta-interferon and simvastatin, an HMG CoA reductase inhibitor, indicate that there is no beneficial effect with add-on therapy (Sorensen et al. Lancet Neurol 2011; 10: 691-701).

It takes 30 seconds

Recommend to a Colleague

Related Posts

Go back to home page